Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention.

Autor: Kilic ID; Department of Cardiology, Pamukkale University Hospitals, Denizli, Turkey., Fabris E; Cardiovascular Department, University of Trieste, Trieste, Italy. enrico.fabris@hotmail.it., Kedhi E; Department of Cardiology, Isala Heart Center, Zwolle, the Netherlands., Ghilencea LN; University of Medicine and Pharmacy Carol Davila, Bucharest, Romania., Caiazzo G; P.O. San Giuseppe Moscati, Aversa, Italy., Sherif SA; Brighton and Sussex Medical School, Brighton, UK., Di Mario C; Cardio-toraco-vascular Department, Careggi University Hospital, Florence, Italy.
Jazyk: angličtina
Zdroj: Current atherosclerosis reports [Curr Atheroscler Rep] 2020 Oct 06; Vol. 22 (12), pp. 76. Date of Electronic Publication: 2020 Oct 06.
DOI: 10.1007/s11883-020-00890-4
Abstrakt: Purpose of Review: Patients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events; therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for secondary prevention for CAD.
Recent Findings: Intra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies and played a role in improving our understanding of the disease processes. Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.
Databáze: MEDLINE
Externí odkaz: